TEMPO.CO, Jakarta - State-pharmaceutical firm Bio Farma announced on Wednesday that it had vaccinated 1,589 volunteers with the Sinovac coronavirus candidate-vaccine in the third phase of the clinical trial.
The initial goal, as previous reports from the firm, states that it would need 1,620 volunteers for the clinical trial.
“The recruitments are nearly complete with 1,589 people that have been injected with the vaccine. We are hoping to obtain an interim analysis by the end of January 2021,” said Bio Farma’s research and development department, Neni Nurainy, in Wednesday’s virtual seminar.
According to her, Bio Farma will also be filing for an emergency use of authorization to the Food and Drug Monitoring Agency (BPOM) before the firm will be able to routinely produce the future vaccine.
She explained that the partnership with Sinovac also includes transfer of technology. The domestic need is expected to overwhelm demands for the vaccine if Indonesia only relies on overseas sources, which is why Indonesia has formed the national vaccine consortium fulfill future large demands for the COVID-19 vaccine.